Diabetic Nephropathy
Kidney damage caused by diabetes, leading to protein leakage in the urine and progressive loss of kidney function.
Emergency Management: Uremic encephalopathy, uremic pericarditis, or life-threatening hyperkalemia (K+ > 6.5 mEq/L with EKG changes) requiring emergent hemodialysis.
Diabetic nephropathy is a chronic microvascular complication of both type 1 and type 2 diabetes mellitus. It is characterized by persistent albuminuria (>300 mg/day) and a progressive decline in glomerular filtration rate (GFR), ultimately leading to end-stage renal disease (ESRD).
Detailed Overview
It is the leading cause of chronic kidney disease (CKD) and ESRD worldwide. Chronic hyperglycemia drives glomerular hyperfiltration, mesangial expansion, and podocyte injury. The disease initially presents silently with microalbuminuria, progressing to macroalbuminuria, and then steadily declining renal function over years. Strict glycemic and blood pressure control are the cornerstones of preventing progression.
Epidemiology & Demographics
Affects 20-40% of patients with diabetes. It is the single leading cause of ESRD in the US, accounting for ~45% of cases. Higher prevalence in African American, Hispanic, and Native American populations.
Etiological Mechanism
Caused by sustained hyperglycemia and uncontrolled hypertension in the setting of long-standing diabetes.
Primary Causes
Type 1 and Type 2 Diabetes Mellitus.
Hyperglycemia leads to accumulation of advanced glycation end products (AGEs), activating protein kinase C and increasing TGF-beta, which promotes fibrosis. Afferent arteriolar vasodilation (from IGF-1 and NO) and efferent arteriolar vasoconstriction (from Angiotensin II) cause glomerular capillary hypertension and hyperfiltration. Over time, this mechanical stress and metabolic injury lead to mesangial cell proliferation, thickening of the glomerular basement membrane, and podocyte loss. The classic histologic lesion is nodular glomerulosclerosis (Kimmelstiel-Wilson nodules). This structural damage increases glomerular permeability, resulting in albuminuria, and eventually destroys nephrons, decreasing GFR.
Diagnostic Criteria & Guidelines
Persistent albuminuria defined as UACR >= 30 mg/g on two of three samples collected over 3-6 months, or persistent reduction in eGFR < 60 mL/min/1.73m2, in a patient with diabetes, without signs of other primary kidney disease.
1. Renin-Angiotensin System block: ACE inhibitors (e.g., Lisinopril 10-40 mg PO daily) or ARBs (e.g., Losartan 50-100 mg PO daily) are indicated for nonpregnant patients with diabetes and UACR >30 mg/g. 2. SGLT2 inhibitors (e.g., Dapagliflozin 10 mg PO daily) are strongly recommended for patients with eGFR >= 20 mL/min/1.73m2 and UACR > 200 mg/g to reduce progression. 3. Optimize HbA1c to < 7% and BP to < 130/80 mmHg.
Second-Line & Adjunctive Therapy
Non-steroidal mineralocorticoid receptor antagonists (e.g., Finerenone 10-20 mg PO daily) to reduce proteinuria and CV events if eGFR >= 25 mL/min/1.73m2. GLP-1 receptor agonists (e.g., Semaglutide) if SGLT2i are not tolerated or insufficient for glycemic control.
Surgical & Procedural Management
Kidney transplantation for ESRD. Dialysis access creation (AV fistula or peritoneal dialysis catheter) when GFR < 15-20 mL/min.
Patient Counseling & Advice
Explain that ACEi/ARBs protect the kidney even if blood pressure is normal. Emphasize that strict blood sugar control early in the disease is the best way to prevent needing dialysis.
Follow-Up & Monitoring Schedule
Annual screening of UACR and eGFR in all type 2 diabetics at diagnosis, and in type 1 diabetics 5 years after diagnosis. If UACR is elevated, monitor every 3-6 months along with serum potassium.
Preventive Strategies
Strict primary glycemic control (HbA1c < 7%) and blood pressure control. Avoiding nephrotoxic agents like NSAIDs and IV contrast when possible.
If untreated, progression from microalbuminuria to macroalbuminuria takes ~5-10 years, and from macroalbuminuria to ESRD takes another 5-10 years. Cardiovascular mortality is the most common cause of death.